Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Current issues in dendritic cell cancer immunotherapy.

José Alejandro López1, Derek N J Hart

  • 1Mater Medical Research Institute, South Brisbane, QLD, Australia.

Current Opinion in Molecular Therapeutics
|March 12, 2002
PubMed
Summary

Dendritic cell (DC) therapies can correct immune defects that allow cancer to develop. These DC-based vaccines boost the immune response to eliminate malignant cells, with early clinical trials showing promising results.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Microfluidic chip enables single-cell measurement for multidrug resistance in triple-negative breast cancer cells.

Cancer drug resistance (Alhambra, Calif.)·2022
Same author

Distinguishing human peripheral blood CD16<sup>+</sup> myeloid cells based on phenotypic characteristics.

Journal of leukocyte biology·2019
Same author

CD300f epitopes are specific targets for acute myeloid leukemia with monocytic differentiation.

Molecular oncology·2019
Same author

CD83: Activation Marker for Antigen Presenting Cells and Its Therapeutic Potential.

Frontiers in immunology·2019
Same author

Examination of CD302 as a potential therapeutic target for acute myeloid leukemia.

PloS one·2019
Same author

The cell surface phenotype of human dendritic cells.

Seminars in cell & developmental biology·2018

Area of Science:

  • Immunology
  • Oncology
  • Cell Biology

Background:

  • Dendritic cells (DCs) are crucial for initiating and directing immune responses.
  • Defects in DC function, particularly in detecting malignant cells, can permit cancer development.
  • Restoring DC function is a potential strategy for cancer immunotherapy.

Purpose of the Study:

  • To investigate the potential of dendritic cell (DC)-based therapies in cancer treatment.
  • To explore how DC-based vaccines/therapies can correct immune defects and enhance anti-cancer immunity.
  • To review the progress and emerging clinical results of DC-based cancer therapies.

Main Methods:

  • Review of current understanding of DC physiology and function in cancer immunity.
  • Analysis of strategies for DC isolation and application in therapeutic vaccines.
  • Evaluation of emerging clinical data from phase I/II trials of DC-based therapies.

Main Results:

  • DC dysfunction is implicated in the evolution of malignant cells into cancer.
  • DC-based vaccines and therapies show potential to correct these immune defects.
  • Early-phase clinical trials (Phase I/II) are yielding encouraging results for various cancer types.

Conclusions:

  • DC-based therapies represent a promising approach to cancer immunotherapy.
  • Advances in DC biology and isolation techniques facilitate clinical applications.
  • Further research and clinical development are warranted to optimize DC-based cancer treatments.

Related Experiment Videos